Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the…
News
Qualigen Therapeutics Divests FastPack® Diagnostics Business
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX,…
Qualigen Therapeutics Divests FastPack® Diagnostics Business
All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX,…
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
Interim Data Analysis anticipated in Early 2024 MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) — Panbela…
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
Interim Data Analysis anticipated in Early 2024 MINNEAPOLIS, July 24, 2023 (GLOBE NEWSWIRE) — Panbela…
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30…
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30…
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
These new appointments bring extensive US and international experience in company leadership and development of…
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
These new appointments bring extensive US and international experience in company leadership and development of…
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic…
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic…
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug…
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug…
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma…
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma…
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
BEDFORD, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused…
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
BEDFORD, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused…
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful results These…